What factors drove the changes in RenovoRx's revenue and profit?

What guidance did RenovoRx's management provide for the next earnings period?

What were the key takeaways from RenovoRx’s earnings call?

What is the market's earnings forecast for RenovoRx next quarter?

What is RenovoRx's latest dividend and current dividend yield?

What were the key takeaways from RenovoRx's earnings call?

What does RenovoRx do and what are its main business segments?

What is RenovoRx's gross profit margin?

- **Leadership Evolution**: Dr. Agah shifts to strategic role, CEO focuses on scaling, and CFO brings high-growth expertise.
- **2025 Financial Milestones**: $1.1M revenue, 88% gross margin, and $10M private placement to fuel 2026 growth.
- **2026 Growth Plan**: Target 36 commercial sites and $3-4M revenue, driven by 17 transitioning trial sites and 21 pipeline centers.
- **Clinical Momentum**: 104/114 patients randomized in TIGeR-PaC trial, with final data in 2027.
- **Q1 2026 Outlook**: Strongest quarter yet, with sequential growth expected throughout the year.

**【CEO Summary Section】**
- **Leadership Transition**: Dr. Ramtin Agah transitioned to Executive Chairman, focusing on clinical strategy, while Shaun Bagai leads commercialization. New CFO Mark Voll brings 30+ years of high-growth med-tech experience.
- **2025 Financials**: Full-year revenue of $1.1 million, Q4 revenue of $238,000, with 88% gross margin. 2026 target: 36 active commercial sites (up from 12) and $3-4 million revenue.
- **Commercial Momentum**: 12 active sites as of Feb 2026, 21 in evaluation pipeline. Q1 2026 expected to be strongest quarter yet, driven by new site activations and physician familiarity from TIGeR-PaC trial.
- **Sales Team Expansion**: 3 dedicated sales reps in 2025, planning to add 2 more in 2026 to cover underserved geographies.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: Revenues $238,000, gross profit $210,000 (88% margin). Full-year R&D: $6.3 million, SG&A: $7 million. Cash balance $7 million as of Dec 31, 2025.
- **2026 Outlook**: Private placement raised $10 million to accelerate sales and clinical trials. Expect growing revenues to reduce cash burn and drive toward breakeven.
- **Financial Discipline**: Capital-efficient growth strategy, with targeted investments in sales and marketing.

**【Q&A Highlights】**
- **Trial to Commercial Transition**: 17 TIGeR-PaC sites expected to transition to commercial use post-enrollment, with minimal training needed. 104/114 patients randomized as of March 2026, on track for final analysis in 2027.
- **Revenue Growth Drivers**: New site activations (36 target by end-2026) and repeat usage at existing sites. Q1 2026 expected to surpass Q4 2025, with sequential growth throughout 2026.
- **Sales Team Sufficiency**: Current 3 reps and planned additions of 2 will be sufficient to achieve 36-site goal, given pipeline of 33+ centers in evaluation.
- **Trial Enrollment Cadence**: 72/86 events observed as of March 2026, with final analysis expected in 2027. Enrollment completion by mid-2026 will enable full commercial focus.


RenovoRx Inc (RNXT) Q4 2025 Earnings Call Transcript

- **Commercial Growth**: Year-to-date revenue of $900,000 with 14 approved centers, up from 5 in 2023, and 24 centers requesting quotes. U.S. market opportunity estimated at $400 million annually.
- **Clinical Progress**: Phase III TIGeR-PaC trial randomized 95 patients (61 events), with enrollment expected to complete in early 2026. Post-marketing registry study launched with three sites.
- **Financial Stability**: $10.1 million in cash as of Q3 2025, sufficient to fund operations into mid-2026. COGS reduced through U.S.-based manufacturing.
- **Strategic Focus**: Prioritizing U.S. market expansion with targeted sales hires, while maintaining fiscal discipline.

**【Management Opening Remarks】**
- Dr. Ramtin Agah highlighted the adoption of the TAMP platform across 14 leading cancer centers, including academic and community hospitals, and the launch of TAMP Workshops for peer-to-peer training. He emphasized the platform's ability to deliver targeted chemotherapy with reduced systemic toxicity.

**【CEO Commentary】**
- Shaun Bagai reported year-to-date revenue of $900,000 through Q3 2025, up from $500,000 in 2024, with 14 centers approved to purchase RenovoCath (up from 5 in 2023). Five centers have already placed repeat orders, and 24 centers have requested quotes. The company hired a Senior Director of Sales and two regional managers, with plans to add a marketing director in 2026. The U.S. market opportunity for RenovoCath is estimated at $400 million annually, with potential expansion into other tumor types.

**【CFO Financial Commentary】**
- Ron Kocak reported Q3 2025 revenue of $266,000, with total R&D and SG&A expenses of $3.4 million. The company ended the quarter with $10.1 million in cash, sufficient to fund operations into mid-2026. COGS have been reduced through a U.S.-based contract manufacturer, and the device has a two-year shelf life.

**【Clinical Updates】**
- Lisa Gentry announced the launch of a post-marketing registry study with three initial sites, generating real-world data on safety and efficacy. The phase III TIGeR-PaC trial, which compares intra-arterial gemcitabine to IV chemotherapy, has randomized 95 patients (61 events) and is expected to complete enrollment in early 2026, with final data in 2027. The Data Monitoring Committee expressed confidence in the trial's potential positive outcome.

**【Q&A Highlights】**
- **International Expansion**: CEO Shaun Bagai stated the company will focus on the U.S. market due to favorable reimbursement and large addressable population, but will monitor international interest.
- **Supply Chain**: The device is manufactured in the U.S. with a 2-year shelf life, allowing for rapid scaling. COGS have been reduced through a strategic partnership.
- **Sales Pipeline**: 24 centers have requested quotes, with dozens more expressing interest. The sales cycle varies from several weeks to months, but can be accelerated with local representation.
- **Clinical Momentum**: The registry study and TIGeR-PaC trial are generating evidence to support broader adoption of TAMP as the fourth pillar of cancer treatment.

RenovoRx Inc (RNXT) Q3 2025 Earnings Call Transcript

- **Commercial Breakthrough**: $422,000 Q2 revenue with 100% organic growth, no dedicated sales team.
- **Clinical Momentum**: DMC recommends continuation of Phase III trial; 95/114 patients randomized, on track for Q1 2026 completion.
- **High Margins**: 64% gross margin in Q2, potential to reach 70%-90% as scale increases.
- **Market Expansion**: $400M U.S. TAM for RenovaCath, with $several billion global potential across solid tumors.
- **Strategic Moves**: Hired Senior Director of Sales, launched PANTHER registry, and preparing for FDA accelerated approval.

**【Management Opening Remarks】**
- Dr. Ramta Nagar highlighted the successful commercial launch of the RenovaCath device, achieving $400,000 in Q2 2025 revenue without a dedicated sales team.
- The Phase III TIGER PACT trial reached its second interim analysis milestone (52nd event), with the DMC recommending continuation of the trial.
- The TAMP platform’s targeted drug delivery approach aims to address unmet needs in pancreatic cancer by minimizing systemic toxicity.

**【CEO Commentary】**
- Sean Bagay emphasized organic revenue growth of $422,000, driven by early adopters and repeat orders, despite no dedicated sales force.
- The company hired Phil Stockton as Senior Director of Sales and Market Development to accelerate commercialization.
- The PANTHER registry study was launched to evaluate RenovaCath’s safety and efficacy in real-world settings across solid tumors.
- The U.S. total addressable market for RenovaCath is estimated at $400 million, with potential expansion into a $several billion global market.

**【CFO Financial Commentary】**
- Q2 2025 revenue: $422,000 (100% commercial, excluding clinical trial offsets).
- R&D expenses: $1.4 million (down $100k YoY due to reduced clinical costs).
- SG&A expenses: $1.5 million (flat YoY).
- Cash reserves: $12.3 million, sufficient to fund commercial scale-up and trial completion.
- Gross margins for RenovaCath are expected to reach 70%-90% as scale increases.

**【Q&A Highlights】**
- **Trial Enrollment**: 95 patients randomized (target 114), with 61 events; enrollment expected to complete by Q1 2026.
- **International Strategy**: Focus on U.S. market first, with potential international expansion post-commercial success.
- **Gross Margins**: Current 64%, with potential to rise to 70%-90% as sales scale.
- **FDA Pathway**: Plans to engage with FDA on accelerated approval post-TIGER PACT completion.
- **Partnerships**: Exploring strategic distributors but prioritizing in-house sales team for now.
- **PANTHER Study**: Centers will purchase RenovaCath for the registry, contributing to revenue and real-world data collection.

RenovoRx Inc (RNXT) Q2 2025 Earnings Call Transcript

- **Revenue Milestone**: $200,000 Q1 2025 sales, exceeding expectations and marking first commercial quarter.
- **Clinical Success**: TIGeR-PaC trial shows 16-month median survival vs. 10-month standard, with 65% fewer adverse events.
- **Market Opportunity**: $400M U.S. peak sales potential for RenovoCath, targeting 7,000 patients annually.
- **Financial Strength**: $14.6M cash on hand, supporting growth without dilution.
- **Strategic Moves**: Exploring international expansion and partnerships to accelerate distribution.

**【CEO Summary Section】**
- **TAMP Therapy Platform**: RenovoRx's transarterial microperfusion (TAMP) technology delivers chemotherapy directly to tumor sites, reducing systemic toxicity. Phase 3 TIGeR-PaC trial interim data shows median overall survival of 16 months (vs. 10 months with standard therapy) and a 65% reduction in adverse events like nausea and fatigue.
- **Clinical Reception**: Over 20 trial sites and 10 non-trial institutions are now considering RenovoCath purchases, with high-volume cancer centers expressing strong interest.

**【CEO Commentary】**
- **Q1 2025 Revenue**: $200,000 from RenovoCath sales, exceeding expectations and marking the first quarter of commercial revenue generation.
- **Market Potential**: Estimated $400 million U.S. peak annual sales for RenovoCath, targeting 7,000 initial patients with 8 annual procedures each. Devices are priced between $6,500-$8,500, similar to competitive products.
- **Growth Strategy**: Sequential quarterly revenue increases expected, with a focus on top 200 high-volume cancer centers. Exploring partnerships with established sales forces to accelerate distribution.
- **Financial Health**: $14.6 million cash on hand as of Q1, sufficient to fund commercial scale-up and Phase 3 trial completion.

**【CFO Financial Commentary】**
- **Revenue**: $200,000 from RenovoCath sales, up from $0 in Q1 2024.
- **Expenses**: R&D ($1.7M vs. $1.3M YoY) and SG&A ($1.6M vs. $1.2M YoY) driven by commercialization costs, manufacturing scale-up, and conference participation.
- **Cash Position**: $14.6 million as of March 31, 2025.

**【Q&A Highlights】**
- **International Expansion**: No current CE mark, but exploring European and Asian markets post-U.S. commercialization. Interest from China, Korea, and Japan noted.
- **Distribution Strategy**: Evaluating direct sales force vs. partnerships with companies having interventional oncology/radiology channels. Both options under active consideration for financial efficiency.

Actual	-0.225	-0.27	-0.24	-0.24	-0.22	-0.13	-0.3	-0.07	-0.1	-0.1	-0.11	-0.08	-0.08	-0.08
Forecast	-0.21	-0.155	-0.29	-0.26	-0.29	-0.28	-0.305	-0.13	-0.105	-0.1167	-0.11	-0.08	-0.085	-0.08	-0.08
Surprise	-7.14%	-74.19%	+17.24%	+7.69%	+24.14%	+53.57%	+1.64%	+46.15%	+4.76%	+14.31%	0.00%	0.00%	+5.88%	0.00%	0.00%

Actual	0	0	0	0	0	--	0	0	0	0	43.00K	197.00K	422.00K	266.00K	--
Forecast	0	0	0	0	0	0	0	0	0	0	0	183.33K	329.63K	405.40K	419.70K
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+7.45%	+28.02%	-34.39%	0.00%

RNXT

RNXT fundamentals

RNXT Q4 2025 Earnings Preview

Earnings Call

You can ask Aime

RNXT

RNXT fundamentals

RNXT Q4 2025 Earnings Preview

Earnings Call

RNXT Earnings Call Summary for Q4/20254:30 PM on Mar 30, 2026

RNXT Earnings Call Summary for Q3/20254:30 PM on Nov 13, 2025

RNXT Earnings Call Summary for Q2/20254:30 PM on Aug 14, 2025

RNXT Earnings Call Summary for Q1/20254:30 PM on May 15, 2025

RNXT Earnings Call Summary for Q4/2024 Apr 1, 2026

You can ask Aime